BRVE

Braveheart Bio, Inc. BRVE

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q3 2026
$202 total
SBI Securities Co., Ltd.
$202--
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BRVE

Earnings Per Share

13fpro.ai/company/BRVE

Loading ratio trend…

BRVE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Braveheart Bio, Inc. (BRVE): stock profile, AI score and financials

Braveheart Bio, Inc. (BRVE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BRVE is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. BRVE trades on the Nasdaq exchange and files with the SEC under CIK 2131524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BRVE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Braveheart Bio, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 2131524 →